和黄医药(0013.HK)于2025年1月1日公告,卖方(公司的全资附属公司)于2024年12月31日:就以总购买价人民币3,482,627,982元(约4.73亿美元)出售金浦健服待售股份(占上海和黄药业35%的股权)与金浦健服股权投资管理订立金浦健服购股协议。就以总购买价人民币995,036,566元(约1.35亿美元)出售上海医药待售股份(占上海和黄药业10%的股权)与上海医药订立上海医药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.